Ethics & Compliance
Lilly maintains an effective program of ethics and compliance that is designed to meet external requirements and guided by the company's values of integrity, excellence and respect for people.
At Lilly, we are committed to upholding the highest standards of corporate conduct in all business dealings around the world. Our global program of ethics and compliance supports this commitment and is designed to meet all external requirements, including codes issued by the International Federation of Pharmaceutical Manufacturers. Lilly Canada adheres to the Code of Ethical Practices of Innovative Medicines Canada, and we abide by all laws, regulations and policies affecting our industry, including those of Health Canada, the Pharmaceutical Advertising Advisory Board (PAAB), and Advertising Standards Canada (ASC).
The Lilly family’s core values of integrity, excellence and respect for people provide the foundation for this program and continue to guide all that we do today.
The fundamental elements of our program of ethics and compliance include the following:
Eli Lilly and Company’s chief ethics and compliance officer reports to the public policy and compliance committee of Lilly’s board of directors, as well as to the CEO. This individual develops, operates and monitors the program while managing a diverse team that works across the business in all geographies.
If you would like to report a concern regarding Lilly Canada's ethical conduct or practices, please contact the local chief ethics and compliance officer at:
Eli Lilly Canada Inc.
P.O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, Ontario M5X 1B1
The Red Book, which is our code of business conduct, is a statement of principles that guides our operations. These principles are based on 11 corporate policies and are consistent with our company values of integrity, excellence and respect for people. Our global procedures, standards and training align with the code of business conduct, and we hold every employee accountable for making decisions with integrity so we can earn and maintain the trust of the people we serve.
Education and Training
We require all employees to complete ongoing training and education on The Red Book, its associated policies and procedures, and all applicable legal requirements.
We actively promote open communication at all levels of the organization. Our employees understand they have an obligation to speak up when they have questions or concerns about potential violations or unethical behaviour that could harm Lilly or the people we serve. Our leaders are expected to support and promote this open communication. Employees can report concerns to company leaders, as well as to human resources, ethics and compliance, or the legal department. We maintain a hotline which is available to employees and the global public 24 hours a day, subject to local law, via phone at 1-800-815-2481 (primary language English) and 1-855-350-9393 (primary language French), or online at Lilly EthicsPoint. Translation services are available, and reports may be made anonymously.
Auditing and Monitoring
On an ongoing basis, we assess, evaluate, monitor and audit compliance with our program of ethics and compliance and all associated policies and procedures. We report findings to top leaders, local management and corporate governance committees.
Response to Potential Violations
We investigate all reports of potential violations using a standard process. If a violation has occurred, we determine appropriate disciplinary consequences by evaluating each case individually. We also review our procedures, processes and business practices to establish whether changes are needed to prevent further violations.
Program for Maintaining Integrity in Our Business: Working with Health Care Professionals
Health care professionals are important partners to the pharmaceutical industry, as they share with us their scientific and medical expertise, as well as their insights into patients’ care. Collaboration among health care professionals, health care organizations and the research-based pharmaceutical industry has helped produce innovative medicines, vaccines and diagnostics, and has significantly reduced the impact of many diseases on the lives of Canadians.
We maintain a program to enhance transparency and prevent corruption called Integrity in Business, and we created a specific department — Lilly Canada’s Business Integrity Office — to help ensure that our business transactions with health care providers are beyond reproach.
We also believe that transparency regarding our external collaborations strengthens trust, and is in the best interest of Canadians. Consequently, we have taken the initiative to be transparent about our financial relationships with other members of the Canadian health care system. Lilly, along with nine other member-companies of Innovative Medicines Canada, now voluntarily publishes aggregated sums of our company’s payments to Canadian health care practitioners and health care organizations.
To view our publications, please see our Financial Interactions page.